ライフサイエンスコーパス: exhale

1 Serum 3-OMG concentrations and exhaled (13)CO2 (indices of glucose and lipid absorption

2 C) ratio, and forced expiratory volume after exhaling 75% of vital capacity (FEF75), whereas those bo

3 ed by highly transmissible influenza viruses exhale a greater number of aerosol particles and more in

4 fractional concentration of nitric oxide in exhaled air (FeNO) was measured.

5 ted with fraction of exhaled nitric oxide in exhaled air (r = 0.48, P = .004), blood neutrophils (r =

6 frequency of breathing and peak flow rate of exhaled air are necessary parameters to detect chronic o

7 loxanes (D4 and D5) can be quantified in end-exhaled air at concentrations as low as background level

8 s developed for analysis of D4 and D5 in end-exhaled air by thermal desorption gas chromatography mas

9 el successful reproduced observed chloroform exhaled air concentrations resulting from an inhalation

10 The limit of quantification was 2.1 ng/L end-exhaled air for D4 and 1.4 ng/L end-exhaled air for D5.

11 ng/L end-exhaled air for D4 and 1.4 ng/L end-exhaled air for D5.

12 Carbon dioxide (CO(2)) present in exhaled air is the most important sensory cue for female

13 Fifteen consumers provided end-exhaled air samples that were collected using Bio-VOC br

14 e back of the oral cavity are transported by exhaled air through the nasal cavity to stimulate the ol

15 outhpiece of optimal length ensured that the exhaled air was focused on the humidity-sensor.

16 lso measured the fraction of nitric oxide in exhaled air, blood and sputum eosinophils, and airway hy

17 ires, measurement of exhaled nitric oxide in exhaled air, blood sampling for inflammatory biomarkers,

18 The aim of the EASE (Exhale airway stents for emphysema) trial was to evaluat

19 Capnography, the graphic display of the exhaled and inhaled carbon dioxide concentration plotted

20 Different breath tests assay, (1) exhaled antigen 85, (2) mycobacterial urease activity, a

21 itor (PAI-1), and factor XIII (FXIII), NO in exhaled breath (FENO ), spirometry (FEV1 ) and eosinophi

22 In this study, we profiled the exhaled breath (~450 mL) volatile organic compounds (VOC

23 Exhaled breath analysis of volatile organic compounds (V

24 The present study assessed whether exhaled breath analysis using Selected Ion Flow Tube Mas

25 QCL sensing techniques for isotope-selective exhaled breath analysis.

26 from a variety of sources, including airway, exhaled breath and blood.

27 sured carbon monoxide (CO) concentrations in exhaled breath and personal air to assess exposure.

28 electrospray ionization mass spectrometry of exhaled breath and UHPLC-HRMS/MS experiments using exhal

29 for detecting select biomarkers in simulated exhaled breath as a step toward enabling fast and inexpe

30 CO in exhaled breath at the same time as spirometry was associ

31 successfully applied to analyze PCs in human exhaled breath by using a simple and convenient collecti

32 y aimed to apply the metabolomic approach to exhaled breath condensate (breathomics) to discriminate

33 Collection of exhaled breath condensate (EBC) and quantification of bi

34 xhaled nitric oxide measurement, spirometry, exhaled breath condensate (EBC) collection.

35 We sought to investigate whether exhaled breath condensate (EBC) lipoxin and leukotriene

36 Exhaled breath condensate (EBC) metabolite profiles also

37 other readily accessible body fluids such as exhaled breath condensate (EBC), saliva, urine, and bloo

38 rlaps the generally accepted H2O2 content in exhaled breath condensate (EBC), with the sensitivity of

39 ecrease in plasma MCP-1 on day 3 and reduced exhaled breath condensate acidification.

40 mentation of early screening methods such as exhaled breath condensate analysis and low dose computed

41 Biomarkers in exhaled breath condensate and airway resistance (pre- an

42 ease in Tumor Necrosis Factor-alpha level in exhaled breath condensate at week 12.

43 15-epi-lipoxin-A4 was identified in exhaled breath condensate from LAM subjects and was incr

44 e aimed at verifying whether metabolomics of exhaled breath condensate from obese asthmatic (OA) pati

45 e aimed at verifying whether metabolomics of exhaled breath condensate from obese asthmatic (OA) pati

46 enals), biomarkers of lipid peroxidation, in exhaled breath condensate of three healthy subjects (N =

47 Metabolomic profiling of exhaled breath condensate offers opportunities for the d

48 d oxidative stress (exhaled nitric oxide and exhaled breath condensate pH, malondialdehyde, and nitri

49 essed by plasma cytokines and intraoperative exhaled breath condensate pH; alveolar type 1 epithelial

50 tion, benzothiazoles were also determined in exhaled breath condensate samples by means of ultra high

51 Biomarkers in exhaled breath condensate, exhaled volatile organic comp

52 d breath and UHPLC-HRMS/MS experiments using exhaled breath condensate, respectively.

53 Exhaled breath contains thousands of volatile organic co

54 the noninvasive detection of metabolites in exhaled breath could potentially help to address this pr

55 e informativeness of CO concentration in the exhaled breath during systemic infection and inflammatio

56 These included nasal wash fluid and exhaled breath for PCR-based detection of viral RNA, lun

57 Exhaled breath from 14 rats was repeatedly sampled by e-

58 pplied for the quantification of VOCs in the exhaled breath from 3 groups of patients, viz., those wi

59 hy-mass spectrometry (GC-MS) analysis of the exhaled breath from three rats.

60 meliorates immunopathology, is measurable in exhaled breath in individuals with pulmonary tuberculosi

61 Biomarkers from exhaled breath include fractional exhaled nitric oxide,

62 Sampling exhaled breath is a noninvasive alternative to phlebotom

63 atio determination of (12)CO2 and (13)CO2 in exhaled breath is of critical importance in the field of

64 ory symptoms) and spirometry and CO (ppm) in exhaled breath measurements.

65 We describe the analysis workflow to profile exhaled breath metabolites and provide here a first libr

66 rger studies to elucidate the association of exhaled breath metabolites with gender-specific disease

67 rformed to test for associations between the exhaled breath metabolome and sonographic lung abnormali

68 weight, lung function, respiratory symptoms, exhaled breath nitric oxide [eNO], exhaled carbon monoxi

69 traits, including respiratory parameters and exhaled breath nitric oxide.

70 of planktonic or biofilm cultures or in the exhaled breath of adult cystic fibrosis patients with ch

71 enabled us to document baseline compounds in exhaled breath of healthy animals and to study changes i

72 is rapid with maximal detection of (15)N2 in exhaled breath of infected rabbits within 5-10 min.

73 rmining the (12)CO2/(13)CO2 ratio within the exhaled breath of mice.

74 tions of acetonitrile have been found in the exhaled breath of patients with cystic fibrosis1 and may

75 rk shows evidence for real-time detection in exhaled breath of the complete series of saturated linea

76 ore straightforward than those measured from exhaled breath or directly from the airway.

77 of four phosphatidylcholines (PCs) in human exhaled breath particles.

78 Exhaled breath samples were analyzed from 81 patients wi

79 a and identify recognized pathogens of SRKW, exhaled breath samples were collected between 2006-2009

80 of volatile organic compounds (VOCs) within exhaled breath samples.

81 tion of volatile organic compounds (VOCs) in exhaled breath samples.

82 ectable by high through-output techniques in exhaled breath showing a specific pattern of VOCs.

83 Distinct exhaled breath VOC profiles can distinguish patients wit

84 Eleven exhaled breath VOCs were identified from both uni and mu

85 Recently, the presence of these gases in exhaled breath was also correlated with obesity.

86 The highest amount in exhaled breath was found for DPPC with median concentrat

87 extraction platforms, kraft paper mills, and exhaled breath, but its determination at ppb levels rema

88 he detection of benzothiazole derivatives in exhaled breath.

89 he quantification of acetone and isoprene in exhaled breath.

90 diseases and for molecular fingerprinting of exhaled breath.

91 usly to study their relation with acetone in exhaled breath.

92 refore interest in detecting acetonitrile in exhaled breath.

93 latile and nonvolatile compounds in cetacean exhaled breath.

94 n be detected by e-Nose data analysis of the exhaled breath.

95 been chosen for monitoring trace acetone in exhaled breath.

96 ofiling volatile organic compounds (VOCs) in exhaled breath.

97 o detect metabolized propofol from patients' exhaled breath.

98 ic inflammation in humans and is released in exhaled breath.

99 kers (even at p.p.b. levels) in highly humid exhaled breath.

100 or the full omega-oxidation pathway in human exhaled breath.

101 able for the identification of biomarkers in exhaled breath.

102 d peripheral airways and compare it with the exhaled bronchial and alveolar NO levels in patients wit

103 is measurable in droplets and droplet nuclei exhaled by infected ferrets.

104 n-cabin UFPs by approximately 90%, passenger-exhaled carbon dioxide (CO2) can quickly accumulate insi

105 her attractive cues, including body heat and exhaled carbon dioxide (CO2), are common to all warm-blo

106 tion [VO(2)] and ventilatory equivalents for exhaled carbon dioxide [VE/VCO(2)] slope) were compared

107 nd trains) in Cape Town, South Africa, using exhaled carbon dioxide as a natural tracer gas to evalua

108 ey model of tuberculosis transmission, using exhaled carbon dioxide as a tracer gas, to describe tran

109 ial cues available to guide such navigation: exhaled carbon dioxide, a plethora of skin odors, the ho

110 symptoms, exhaled breath nitric oxide [eNO], exhaled carbon monoxide [eCO], and high-resolution compu

111 or more days of continuous abstinence and an exhaled carbon monoxide level of 3 ppm or less.

112 lf-reported smoking or if their preoperative exhaled carbon monoxide level was 10 ppm or higher.

113 Preoperative exhaled carbon monoxide level was not associated with th

114 Smoking status and preoperative exhaled carbon monoxide level, assessed by nurses in the

115 gery and SSI was not related to preoperative exhaled carbon monoxide levels.

116 Cessation was verified by exhaled carbon monoxide levels.

117 abstinence was established and confirmed by exhaled carbon monoxide measurements at TQD and at inter

118 til delivery, as validated by measurement of exhaled carbon monoxide or salivary cotinine.

119 ng behavior, cotinine plasma concentrations, exhaled carbon monoxide, and the Fagerstrom Test (FTND).

120 The primary end point was the 4-week exhaled carbon monoxide-confirmed continuous abstinence

121 f the relapse-prevention phase, confirmed by exhaled carbon monoxide.

122 sociated negatively with microbial richness, exhaled CH4, presence of methanogens, and enterotypes en

123 In our community-based sample, higher exhaled CO levels predicted the development of metabolic

124 Only participants who provided an exhaled CO measurement or self-reported their smoking st

125 However, the relation of exhaled CO to metabolic/vascular risk in the community i

126 Baseline exhaled CO was associated with the presence of cardiomet

127 We related exhaled CO, a surrogate measure of blood CO concentratio

128 d with individuals in the lowest quartile of exhaled CO, those in the highest quartile were more like

129 dly diseases locate human hosts by detecting exhaled CO2 and skin odor.

130 cantly lower, whereas minute ventilation and exhaled CO2 were significantly increased.

131 ct influence on ventilation, oxygenation and exhaled CO2.

132 Exhaled concentrations of sevoflurane strongly depended

133 ectious virus present in respirable aerosols exhaled from infected hosts.

134 lism caused by DNP injection was measured by exhaled gas analysis.

135 For each subject, we measured exhaled H2 and CH4, oro-anal transit time, and the sever

136 bjects; however, limited studies focusing on exhaled human breath are available in the literature.

137 The identification of chemical compounds in exhaled human breath is promising in the search for new

138 s demonstrated with the analysis of 27 nL of exhaled human breath.

139 shing chamber; the resulting flow mimics the exhaled human breath.

140 t-of-care diagnosis of metabolic diseases in exhaled human breath.

141 Concentrations of exhaled hydrogen ions, nitric oxide products, hydrogen p

142 The acetone concentration exhaled in the breath of three type 1 diabetes patients

143 re susceptible to spider-attack because they exhaled less nicotine because of lower hemolymph nicotin

144 , 1.1-2.3); being overweight (1.5, 1.0-2.3); exhaled nitric oxide >/= 20 ppb (1.9, 1.3-2.7); and tota

145 Despite lower fraction of exhaled nitric oxide (30.0 vs 62.6 ppb; P = .037) and re

146 (0.65 vs 0.39, P = 0.021), higher Fractional exhaled nitric oxide (38 ppb vs 25 ppb, P = 0.021) and i

147 Exhaled nitric oxide (eNO) is a biomarker of airway infl

148 Exhaled nitric oxide (eNO), induced sputum cell counts,

149 A marker of airway inflammation [exhaled nitric oxide (eNO)], respiratory symptom surveys

150 , response to salmeterol, degree of EIB, and exhaled nitric oxide (FE(NO)) at baseline were examined

151 ify a test for nonadherence using fractional exhaled nitric oxide (Fe(NO)) suppression after directly

152 hildren's phthalate exposures and fractional exhaled nitric oxide (Fe(NO)), a biomarker of airway inf

153 ssessing the predictive value of fraction of exhaled nitric oxide (FENO ) for persistence of wheezing

154 Fractional exhaled nitric oxide (FENO ) was measured.

155 Fraction of exhaled nitric oxide (Feno) and blood eosinophil count (

156 of airway inflammation including fractional exhaled nitric oxide (FeNO) and sputum eosinophils would

157 the association between baseline fractional exhaled nitric oxide (FeNO) and the response to inhaled

158 Exhaled nitric oxide (FeNO) associates with asthma and e

159 relation to the asthma biomarker fractional exhaled nitric oxide (FeNO) in 155 subjects with asthma

160 microarray technique (BioIC) and fraction of exhaled nitric oxide (FeNO) in a population sample of 13

161 Fractional exhaled Nitric Oxide (FeNO) is a biomarker for eosinophi

162 The fraction of exhaled nitric oxide (FENO) is a useful marker of asthma

163 On the other hands, the fraction of exhaled nitric oxide (FENO) is a useful noninvasive mark

164 e have previously described that fraction of exhaled nitric oxide (Feno) levels and blood eosinophil

165 nts undergoing airway challenge, fraction of exhaled nitric oxide (FENO) levels decrease after bronch

166 The significance of fractional exhaled nitric oxide (Feno) levels in children with sick

167 nophil counts, total IgE levels, fraction of exhaled nitric oxide (Feno) levels, or FEV1 percent pred

168 were able to perform acceptable fraction of exhaled nitric oxide (Feno) maneuvers and spirometry (wi

169 , measurement of fractional concentration of exhaled nitric oxide (Feno) provides an in vivo assessme

170 The added value of fractional exhaled nitric oxide (Feno) remains controversial in the

171 The fraction of exhaled nitric oxide (Feno) value is a biomarker of eosi

172 wheeze and asthma and increased fraction of exhaled nitric oxide (Feno) values in children.

173 The increased fraction of exhaled nitric oxide (Feno) values observed in asthmatic

174 y accessible biomarkers included fraction of exhaled nitric oxide (Feno) values, blood eosinophil (bE

175 ween 25% and 75% [FEF25-75]) and fraction of exhaled nitric oxide (Feno) were made at 14 to 15 years

176 cohort, we assessed whether the fraction of exhaled nitric oxide (FeNO), a biomarker of airway infla

177 Biomarkers, such as the fraction of exhaled nitric oxide (Feno), allow further tailoring of

178 ction, bronchial responsiveness, fraction of exhaled nitric oxide (Feno), and allergic sensitization.

179 lf-reported eczema ever, measured fractional exhaled nitric oxide (FeNO), and interrupter resistance

180 th respiratory resistance (Rint), fractional exhaled nitric oxide (Feno), and risks of wheezing and a

181 airway inflammation, assessed by fraction of exhaled nitric oxide (FeNO), in a population-based study

182 at 18 years of age, with normal fraction of exhaled nitric oxide (Feno), low bronchial hyperresponsi

183 Repeated measures of exhaled nitric oxide (FeNO), lung function (FEV1, FVC),

184 Results of spirometry, fractional exhaled nitric oxide (Feno), mannitol provocation testin

185 We measured fraction of exhaled nitric oxide (Feno), peripheral blood eosinophil

186 ionnaire, spirometry, skin prick test (SPT), exhaled nitric oxide (FeNO), smell test, and peak nasal

187 nts to measure total eosinophils, fractional exhaled nitric oxide (Feno), sputum eosinophils, urinary

188 All patients underwent blood tests, exhaled nitric oxide (FeNO), sputum induction, bronchoal

189 and induced sputum collection and fractional exhaled nitric oxide (FeNO).

190 and bronchial inflammation with fraction of exhaled nitric oxide (Feno).

191 nction tests, and measurement of fraction of exhaled nitric oxide (FeNO).

192 nflammation was measured daily as fractional exhaled nitric oxide (FeNO).

193 ometry, methacholine and mannitol challenge, exhaled nitric oxide (FeNO); Asthma Control Questionnair

194 The importance of monitoring exhaled nitric oxide (NO) in asthma remains controversia

195 INTRODUCTION: Increased exhaled nitric oxide (NO) levels in asthma are suggested

196 Increased exhaled nitric oxide (NO) levels in asthma are suggested

197 ion, including blood eosinophils (P = .001), exhaled nitric oxide (P = .003), and epithelial CLCA1 (P

198 ones, 3.0 [95% CI, 2.4-3.7]), and changes in exhaled nitric oxide (placebo, -3.48 ppb [95% CI, -5.99

199 Baseline fraction of exhaled nitric oxide (r= -0.55; P= .01) and ventilation

200 nchodilator reversibility >/=12%, fractional exhaled nitric oxide [FeNO] >/=35 parts per billion, and

201 of inflammatory biomarkers (ie, fraction of exhaled nitric oxide [Feno], sputum eosinophil count, an

202 Allergen-induced levels of fractional exhaled nitric oxide and airway hyperresponsiveness to m

203 Exhaled nitric oxide and B-Eos values offered independen

204 pulmonary inflammation and oxidative stress (exhaled nitric oxide and exhaled breath condensate pH, m

205 ssessment (Asthma Control Test), spirometry, exhaled nitric oxide and induced sputum evaluation.

206 differences in sputum neutrophil counts and exhaled nitric oxide and serum IgE levels.

207 ted FEV1 percent predicted, symptom control, exhaled nitric oxide and urinary LTE4 levels.

208 , RV, TLC, DLCO, and KCO) and measurement of exhaled nitric oxide before HSCT and 3, 6, and 12 months

209 Fractional exhaled nitric oxide could be assessed in relation to 25

210 eline bronchodilator response and fractional exhaled nitric oxide had good sensitivity and specificit

211 rticulate oxidative burden as a predictor of exhaled nitric oxide in children with asthma.

212 a, YKL-40 levels correlated with fraction of exhaled nitric oxide in exhaled air (r = 0.48, P = .004)

213 ocol included questionnaires, measurement of exhaled nitric oxide in exhaled air, blood sampling for

214 d value or >/=15% increase), (3) fraction of exhaled nitric oxide levels (<24 ppb), and (4) sputum eo

215 l polyposis (54% vs 27%, P </= .001), higher exhaled nitric oxide levels (38 vs 27 ppb, P = .02) and

216 onchodilator response (P = 0.03), and higher exhaled nitric oxide levels (P = 0.04) compared with the

217 ncrease in sputum eosinophils and fractional exhaled nitric oxide levels affected by treatment.

218 here was no farm effect on lung function and exhaled nitric oxide levels in the general study populat

219 Induced sputum cells and fractional exhaled nitric oxide levels were used to assess airway i

220 iomarkers sputum eosinophilia and fractional exhaled nitric oxide levels, along with oral corticoster

221 ital capacity percentage values, fraction of exhaled nitric oxide levels, and bronchodilator reversib

222 rgest cluster, had normal lung function, low exhaled nitric oxide levels, and lower inhaled steroid r

223 evels, sputum eosinophil counts, fraction of exhaled nitric oxide levels, and serum periostin levels,

224 Spirometry, lung volumes, exhaled nitric oxide levels, and systemic biomarker leve

225 osal eosinophils, as well as high fractional exhaled nitric oxide levels, exacerbation rates, and ora

226 ergen-specific IgE antibody, and fraction of exhaled nitric oxide levels.

227 significantly with total IgE and fraction of exhaled nitric oxide levels.

228 bronchodilator responsiveness and fractional exhaled nitric oxide levels.

229 trolled asthma had worse FEV(1), fraction of exhaled nitric oxide measured at 200 mL/s (Feno), Scond,

230 nitric oxide sensor, and the performance of exhaled nitric oxide measurement was in good agreement w

231 aires, atopy and pulmonary function testing, exhaled nitric oxide measurement, and blood collection.

232 All had exhaled nitric oxide measurement, methacholine test, euc

233 Children performed exhaled nitric oxide measurement, spirometry, exhaled br

234 irometry, including bronchodilator tests and exhaled nitric oxide measurements.

235 Fractional exhaled nitric oxide monitoring revealed changes in FeNO

236 Neither exhaled nitric oxide nor airway responsiveness to methac

237 n response, 28 (52%) of 54 had a fraction of exhaled nitric oxide response, and 29 (54%) of 54 had a

238 V) was built and integrated into a hand-held exhaled nitric oxide sensor, and the performance of exha

239 sputum eosinophils) or baseline fraction of exhaled nitric oxide to stratify patients by eosinophili

240 points for IgE levels (268 IU), fraction of exhaled nitric oxide values (14.5 ppb), and blood eosino

241 x and rhinitis, bronchial reversibility, and exhaled nitric oxide values (all P < 0.05).

242 ls, blood eosinophil counts, and fraction of exhaled nitric oxide values in relationship to sputum eo

243 cts performed spirometry and had fraction of exhaled nitric oxide values measured twice during the sc

244 erresponsiveness to mannitol and fraction of exhaled nitric oxide values were measured.

245 factors, allergic sensitization, fraction of exhaled nitric oxide values, spirometric measurements, a

246 Levels of fractional exhaled nitric oxide were also measured.

247 ssment-based adjustment and biomarker-based (exhaled nitric oxide) adjustment, the dose of inhaled co

248 lammation (blood eosinophils and fraction of exhaled nitric oxide).

249 tors for allergic rhinitis were 25% for high exhaled nitric oxide, 22% for allergic sensitization to

250 rometry, plethysmography, sputum cell count, exhaled nitric oxide, airway hyperresponsiveness to mann

251 and important risk factors include elevated exhaled nitric oxide, allergic sensitization to common h

252 Children also underwent spirometry, exhaled nitric oxide, allergy skin testing to 10 common

253 impulse oscillometry, alveolar and bronchial exhaled nitric oxide, and a methacholine provocation.

254 clinical outcome measures (FEV1, fraction of exhaled nitric oxide, and blood eosinophils) were assess

255 pes of asthma by using blood, bronchoscopic, exhaled nitric oxide, and clinical data from the Severe

256 -gal had normal lung function, low levels of exhaled nitric oxide, and low prevalence of asthma sympt

257 cs such as atopy, lung function, fraction of exhaled nitric oxide, and medication use were calculated

258 uiet natural sleep included tidal breathing, exhaled nitric oxide, and multiple breath washout measur

259 objective markers, such as lung function and exhaled nitric oxide, and their interrelation with atopy

260 nation of blood eosinophil count, fractional exhaled nitric oxide, Asthma Control Questionnaire, medi

261 level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass ind

262 ge, body mass index, FEV1, PC20, fraction of exhaled nitric oxide, blood eosinophil counts, and inhal

263 Skin prick testing, lung function tests, exhaled nitric oxide, hematimetry, and total serum IgE w

264 rkers from exhaled breath include fractional exhaled nitric oxide, measurement of which can help iden

265 els with percent predicted FEV1, fraction of exhaled nitric oxide, or asthma symptoms.

266 escue therapy, pulmonary function), based on exhaled nitric oxide, or on a day-to-day basis guided by

267 ma, or acute urticaria underwent spirometry, exhaled nitric oxide, questionnaires, and serum IgE anti

268 2 airway inflammation, including fractional exhaled nitric oxide, serum IgE, periostin, and blood an

269 er clinical biomarkers for asthma, including exhaled nitric oxide, total serum IgE and pulmonary func

270 he allergen challenge and in the fraction of exhaled nitric oxide.

271 randomisation groups in FEV1 or fraction of exhaled nitric oxide.

272 [101 completed], n = 115 to biomarker-based [exhaled nitric oxide] adjustment [92 completed], and n =

273 nvestigated relationships between fractional exhale NO (FENO) and initial pulmonary tuberculosis seve

274 After measuring the fraction of exhaled NO (Feno [ppb]) at 50, 100, 150, and 200 mL/s, t

275 Exhaled NO (FeNO) is a marker of inflammation in asthma

276 asthma severity or by levels of fraction of exhaled NO (FENO), a biomarker of airway inflammation.

277 ST2 predicts asthma and asthma with elevated exhaled NO (FeNO), compared to the commonly used Asthma

278 Measurements of exhaled NO at multiple constant flows were performed.

279 Increased versus normal exhaled NO during outpatient exacerbation in patients wi

280 Increases in exhaled NO gas were observed in lambs while breathing th

281 The alveolar component of exhaled NO is associated with the lack of asthma control

282 Exhaled NO was measured at different flow-rates and Calv

283 Exhaled NO was measured, and alveolar concentration and

284 typic traits, sputum and blood eosinophilia, exhaled NO, serum cytokines and chemokines, total serum

285 esponsiveness and epithelial mast cells with exhaled NO.

286 penes and one ester were identified from the exhaled nose-space.

287 precolumn in the LC system and to collecting exhaled particles in an electret polymer filter.

288 re the amount of infectious virus present in exhaled respirable aerosols.

289 idgut into hemolymph, from which nicotine is exhaled through the spiracles as an antispider signal.

290 tive and negative likelihood ratios (LR) for exhaled VOC profiles were calculated; and publication bi

291 ly validated studies are needed to introduce exhaled VOC profiling in a clinical scenario.

292 Adding information on exhaled VOCs and possibly expression of inflammation gen

293 esults from the revised studies suggest that exhaled VOCs are promising biomarkers for asthma diagnos

294 matic search for published studies regarding exhaled VOCs in asthma diagnosis was conducted based on

295 Exhaled VOCs pattern from CRC patients is modified by ca

296 Information on exhaled VOCs significantly improved asthma prediction (A

297 ht relationship between tumor metabolism and exhaled VOCs.

298 assess the value and classification rate of exhaled volatile organic compounds (VOCs) in asthma diag

299 Biomarkers in exhaled breath condensate, exhaled volatile organic compounds (VOCs), gene expressi

300 ing of specific cell markers by detection of exhaled xenon gas.